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Background: Influenza vaccination during pregnancy can prevent serious illness in expectant mothers and provide
protection to newborns; however, historically uptake has been limited due to a number of factors, including safety
concerns. Symptomatic complaints are common during pregnancy and may be mistakenly associated with
reactions to trivalent influenza vaccine (TIV). To investigate this, we compared post-vaccination events self-reported
by pregnant women to events reported by non-pregnant women receiving TIV.
Methods: A prospective cohort of 1,086 pregnant women and 314 non-pregnant female healthcare workers
(HCWs) who received TIV between March-May 2014 were followed-up seven days post-vaccination to assess local
and systemic adverse events following immunisation (AEFIs). Women were surveyed by text message regarding
perceived reactions to TIV. Those reporting an AEFI completed an interview by telephone or mobile phone to
ascertain details. Logistic regression models adjusting for age and residence were used to compare reactions
reported by pregnant women and non-pregnant HCWs.
Results: Similar proportions of pregnant women and non-pregnant, female HCWs reported ≥1 reaction following
vaccination with TIV (13.0% and 17.3%, respectively; OR = 1.2 [95% CI: 0.8-1.8]). Non-pregnant, female HCWs were more
likely to report fever or headache compared to pregnant women (OR: 4.6 [95% CI 2.1-10.3] and OR: 2.2 [95% CI 1.0-4.6],
respectively). No other significant differences in reported symptoms were observed. No serious vaccine-associated
adverse events were reported, and less than 2% of each group sought medical advice for a reaction.
Conclusions: We found no evidence suggesting pregnant women are more likely to report adverse events following
influenza vaccination when compared to non-pregnant female HCWs of similar age, and in some cases, pregnant
women reported significantly fewer adverse events. These results further support the safety of TIV administered in
pregnant women.
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The World Health Organisation has identified pregnant
women as the highest priority for influenza vaccination [1].
Despite national recommendations in Australia and the
availability of free vaccine under the National Immunisa-
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sonal influenza [2,3]. A number of studies have confirmed
influenza antenatal vaccination is safe for mother and baby
[4-10]. However, continued monitoring is warranted, con-
sidering the antigenic composition can vary from year to
year and ongoing concerns about side-effects remain a
common factor contributing to non-vaccination among
antenatal patients [2,11-13]. Even the expectation of
minor post-vaccination reactions can negatively affect
the decision to be immunised against influenza [14,15].
Pregnancy can be associated with a variety of symptomaticThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ported by antenatal influenza vaccine recipients is currently
unknown. To assess this, we compared post-vaccination
reactions among pregnant women to those reported by
non-pregnant females of similar age in Western Australia.
Methods
In 2012, the Western Australia Department of Health
(WA-DOH) initiated a program for active surveillance of
adverse events following immunisation (AEFI) in pregnant
women. The Follow-up and Active Surveillance of Triva-
lent influenza vaccine in Mums (FASTMum) program fol-
lows up a subset of pregnant women who receive trivalent
influenza vaccine (TIV), beginning in March each year.
Antenatal women receiving government-procured TIV are
asked by their provider at the time of immunisation if they
are willing to be contacted by the WA-DOH for quality as-
surance purposes. In 2014, the opportunity for post-
vaccination follow-up was extended to healthcare workers
(HCWs) immunised against influenza at government hos-
pitals and health centres.
Using an automated system, pregnant women and
HCWs consenting to follow up were sent a short mes-
sage service (SMS) seven days after they had been vacci-
nated with TIV. The SMS read:
“This is a message from the WA Department of
Health. Our records show that you recently had a flu
vaccine and we are conducting routine follow up.
Please respond Y if you experienced any kind of
reaction, fever, or illness in the week following your
vaccination, or N if there was no reaction”.
Persons who replied “Y”, “yes” or some other affirma-
tive response by SMS were sent a follow-up message
soliciting details regarding the possible AEFI they re-
ported experiencing. The second message read:
“Thank you, your ongoing health is important to us.
Please click here to answer a five minute survey about
your reaction. Alternatively, please respond CALL if
you would prefer to be telephoned about your
reaction”.
The second SMS included an embedded link to a survey
which could be completed on a mobile phone. Research
nurses subsequently attempted to telephone and interview
anyone who had not responded to either the first or second
SMS, or had not completed the mobile phone survey, as
well as those who had replied “Call” by SMS.
For this analysis, all non-pregnant, female healthcare
workers (HCWs) in the follow-up program, who were of
reproductive age and were vaccinated with the same brand
of TIV, i.e. Vaxigrip® (Sanofi Pasteur) were selected forcomparison with pregnant women. Female HCWs were
eligible for the analysis if they were between the ages of 18
and 45 years and had indicated on their consent form that
they were not pregnant at the time of vaccination. The ma-
jority (82%) of pregnant women included in the analysis
were in their second or third trimester of pregnancy; 93%
of reported vaccinations in pregnant women and non-
pregnant female HCWs were included in the follow-up.
Participants who provided no telephone number (5%), pro-
vided only a home telephone number (2%) or an incorrect
mobile telephone number (<1%) on their consent form
were excluded. Ethics approval for this assessment was
obtained by the University of Western Australia Human
Research Ethics Committee (RA/4/1/6095).
Survey instrument
The mobile phone and telephone questionnaires asked if
the vaccinee had experienced fever, headache, fatigue,
rigors, convulsions, vomiting, or pain or swelling at the in-
jection site - indicated by a “yes” or “no” response to each.
The presence or absence of other symptoms was solicited
and, if present, recorded verbatim. Respondents were also
asked to recall the time between vaccination and first
symptom onset as well as the duration of any symptoms
reported. Consumption of over-the-counter antipyretic or
pain relievers following the vaccination was queried, as well
as whether the vaccinee had called a general practitioner
(GP) or other health service for telephone medical advice
regarding the reaction, or had visited a GP, after-hours
clinic, or emergency department (ED) to receive treatment
for a reported reaction.
Outcome measurement
The occurrence of any AEFI was defined as a “yes” re-
sponse to the initial SMS message. A systemic reaction was
defined as a “yes” response to fever, headache, fatigue,
vomiting, rigors, or self-reported cold and flu-like symp-
toms, myalgia, nausea, or malaise. A local reaction was de-
fined as replying “yes” to pain or swelling at the injection,
or self-reported redness at the site of injection. A reaction
requiring telephone advice was defined as any AEFI where
the woman reported calling a GP, a nurse helpline, or other
healthcare service for advice regarding their reaction. A re-
action requiring medical attention was defined as any AEFI
where the woman reported visiting a GP or other health
service for the reaction. An AEFI requiring treatment in-
cluded any AEFI which was self-treated with an anti-
pyretic/analgesic following vaccination and those receiving
treatment by a medical professional.
Statistical analysis
Statistical analysis was performed using SAS version 9.3
(SAS Institute, North Carolina, United States). Overall re-
sponse rate was calculated based on the proportion of
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vided complete details regarding any adverse events out of
all women contacted. Initial comparisons between AEFI re-
ported by pregnant women and non-pregnant, female
HCWs were made using Fisher’s exact test. Adjusted ana-
lyses controlling for demographic differences observed be-
tween groups were performed using multivariate logistic
regression models. Differences in the mean symptom onset
and symptom duration were compared with independent
sample t-tests using the Satterthwaite approximation for
degrees of freedom. A power analysis indicated the ac-
quired sample size was sufficient to determine differences
between groups at a power level of 0.98.
Results
Between 19 March and 15 May 2014, a total of 1,400
women (1,086 pregnant and 314 non-pregnant HCW)
were sent the SMS asking about possible AEFI (Figure 1);
1,205 (86%) women replied by SMS (918 [85%] pregnant
and 287 [91%] non-pregnant), and another 71 (64 [6%]
pregnant and 7 [2%] non-pregnant) did not reply but
were surveyed later by telephone. A total of 52 women
(35 [4%] pregnant and 17 [6%] non-pregnant) who re-
plied to the initial SMS and indicated they had experi-
enced a reaction did not provide AEFI details and were
excluded from analysis. The final analysis included 947
pregnant women and 275 non-pregnant women. The
overall response rates in pregnant women (87.2% [95%
CI 85.2-89.2%]) and non-pregnant, female HCWs (87.6%
[95% CI 83.9-91.2%]) were similar (p > .05).
Two significant differences in demographic character-
istics were observed between the cohorts of pregnant
women and non-pregnant, female HCWs included in
our study. Non-pregnant, female HCWs were on average
2.6 years older than our cohort of pregnant women
(33.7 years vs. 31.1 years, respectively, p < .01), and were
also more likely to reside in a non-urban area (47.8%
[95% CI 42.2-53.3%]) compared to pregnant women
(15.6% [95% CI 13.3-17.9%]; p < .01). The greater propor-
tion of non-pregnant female HCWs residing in non-
urban areas is likely because many metropolitan health
care facilities offered HCWs an intra-dermal influenza
vaccine in preference to Vaxigrip® (Sanofi Pasteur).
A total of 192 (15.7%) women reported a suspected reac-
tion, with similar proportions of pregnant and non-
pregnant, female HCWs reporting at least one AEFI
(13.0% [95% CI 11.0-15.0%] and 17.3% [95% CI 13.0-
21.6%], respectively; p = .34) (Table 1). The rate of reaction
was constant for both pregnant women and non-pregnant,
female HCWs throughout the study period (Figure 2). The
most common reaction reported by both pregnant and
non-pregnant HCWs was a local reaction (4.5% [95%
CI 3.4-6.1%] and 7.3% [95% CI 4.1-10.5%], respectively,
p = .13). No serious vaccine-associated reactions werereported. Systemic reactions were reported by similar pro-
portions of pregnant women and non-pregnant, female
HCWs, overall (9.0% and 10.2% among pregnant women
and non-pregnant HCWs, respectively). However, fever
(OR 4.6 [95% CI 2.1-10.3]) and headache (OR 2.2 [95% CI
1.0-4.6]) were both reported more frequently by non-
pregnant HCWs than pregnant women. Four of the 16
non-pregnant HCWs and five of the 46 pregnant women
who reported a fever reported measuring their temperature.
On average, reported fever began within 24 hours of vac-
cination (median: 24 hours; IQR: 6–48 hours) and lasted
between 8–120 hours (median: 27 hours; IQR: 12–48
hours). The time to onset and duration of fever were simi-
lar in pregnant women and non-pregnant, female HCWs
(p = .52 and p = .14, respectively). Other reported systemic
reactions usually occurred within 24 hours of vaccination
(median: 24 hours; IQR: 6–48 hours) and lasted for a me-
dian of 48 hours (IQR: 24–72 hours). The onset and dur-
ation of these reactions did not differ between pregnant
women and non-pregnant, female HCWs (p = .26 and
p = .21, respectively). Local reactions typically began on the
day of vaccination (median: 8 hours; IQR: 3–24 hours) and
had a median duration of 48 hours (IQR: 24–72 hours).
The onset and duration of local reactions did not differ be-
tween pregnant women and non-pregnant, female HCWs
(p = .18 and p = .24, respectively).
Almost twice as many non-pregnant, female HCWs re-
ported a reaction for which they obtained some form of
treatment, such as self-treatment with an antipyretic or pain
reliever or treatment by a doctor, medical centre or hospital
emergency department (10.7% [95% CI 6.6-14.8%]) com-
pared with pregnant women (5.5% [95% CI 4.0-7.0%]).
However, this difference was not statistically significant
(p = .06) (Table 2). This difference in proportion of reac-
tions treated between pregnant and non-pregnant, fe-
male HCWs can be largely attributed to the increased
rates of fever and headache reported by non-pregnant,
female HCWs. Among women reporting any reaction,
headache and fever were the only symptoms signifi-
cantly associated with seeking some form of treatment
(p = .03 and p < .01, respectively). Reactions requiring tele-
phone advice or medical attention were uncommon in both
pregnant women and non-pregnant, female HCWs (1.3%
[95% CI 0.5-2.0%] vs 0.4% [95% CI 0.0-1.2%], p = .25).
Four pregnant women reported attending a hospital emer-
gency department in the week following influenza vaccin-
ation. One woman reported fever and rigors, a second
reported gastroenteritis, the third reported an upper respira-
tory tract infection, and the fourth woman reported nausea,
dizziness, malaise and a miscarriage. Follow-up assessment
by the physician caring for the woman who reported a mis-
carriage indicated the woman had a history of obstetric
complications, including polycystic ovarian syndrome and
multiple previous miscarriages. The physician reported the
Figure 1 Follow-up of adverse events following trivalent influenza vaccine in pregnant women and non-pregnant female healthcare
workers – FASTMum, Western Australia, Australia, 19 March- 15 May 2014.
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likely to be related to vaccination.
Discussion
We used SMS to collect information on post-influenza
vaccination events in a sample of pregnant and non-
pregnant women, and found no evidence that pregnant
women are more likely to experience a reaction follow-
ing administration of the 2014 influenza vaccination
when compared to non-pregnant, female HCWs of simi-
lar age. Using active surveillance, we found that 1-in-10
pregnant women experienced some sort of reaction, but
fewer than 2% developed a fever. These results were
similar for non-pregnant, female HCWs, although this
group reported slightly higher rates of fever and head-
ache. The most common side-effect reported by eithergroup was a local reaction at the injection site, occurring
in about one of every 15–20 women vaccinated. This in-
formation is useful in reassuring pregnant women and
antenatal immunisation providers regarding the reacto-
gencity of seasonal influenza vaccination during preg-
nancy. However, because the antigenic characteristics of
the influenza vaccine can change from year to year, on-
going assessments of safety and reactogencity are war-
ranted. Secondarily, these results indicate that SMS is a
feasible method of rapidly collecting data for monitoring
vaccine safety in both pregnant and non-pregnant
women.
Previous active surveillance initiatives in Western
Australia in 2012 [9] and 2013 [10] found AEFI rates
similar to those reported here for the 2014 influenza
vaccine. Comparable rates of AEFI among pregnant
Table 1 Adverse events following influenza immunisation reported by pregnant and non-pregnant women – FASTMum,
Western Australia, Australia, 19 March-15 May 2014
Pregnant (n = 947) Non-pregnant (n = 275) Fisher’s exact
test p-value
AOR
p-valuen Percent (95% CI) n Percent (95% CI)
Any reaction** 141 13.0 (11.0-15.0) 51 17.5 (13.1-21.8) .19 .33
Systemic reaction 85 9.0 (7.1-10.8) 28 10.2 (6.6-13.8) .55 .36
Fever 15 1.6 (0.8-2.4) 16 5.8 (3.0-8.6) <.01* <.01*
Headache 27 2.9 (1.8-3.9) 13 4.7 (2.2-7.3) <.01* .04*
Fatigue 40 4.2 (2.9-5.5) 13 4.7 (2.2-7.3) .74 .68
Vomiting 7 0.7 (0.2-1.3) 0 (0.0-0.7) .36 .95
Rigors 5 0.5 (0.1-1.0) 2 0.7 (0.0-1.7) .66 .89
Cold/flu-like 37 3.9 (2.7-5.1) 10 3.6 (1.4-5.9) .50 .69
Myalgia 11 1.2 (0.5-1.8) 5 1.8 (0.2-3.4) .37 .71
Nausea 8 0.8 (0.3-1.4) 1 0.4 (0.0-1.1) .69 .59
Malaise 4 0.4 (0.0-0.8) 1 0.4 (0.0-1.1) .69 .51
Local reaction 45 4.8 (3.4-6.1) 20 7.3 (4.2-10.4) .13 .13
Other reaction 6 0.6 (0.1-1.1) 2 0.7 (0.0-1.7) .57 .89
**Any reaction was defined as replying “yes” to the question “did you experience any fever, illness, or reaction following your vaccination?”.
*Significant at α = .05.
AOR, adjusted odds ratio – adjusted for age and residence (metropolitan/non-metropolitan).
CI, confidence interval.
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In the United States, Nordin et al. [16] investigated the
incidence of medically-attended events in pregnant
women 42 days following TIV vaccination, finding a low
frequency of such events and no increased risk of
medically-attended events in pregnant women. Screen-
ing of the Vaccine Adverse Event Reporting System in
the United States has also indicated there are no differ-
ences in pregnancy complications or fetal outcomes,Figure 2 Proportion of pregnant and non-pregnant women reporting an
Western Australia, Australia, 19 March- 15 May 2014.including spontaneous abortion, in pregnant women
who receive TIV [17]. However, the majority of vaccine
safety studies in pregnant women, including our own,
have been observational in nature [18].
To our knowledge, this is the first study to directly
compare the reactogenicity of influenza vaccine in preg-
nant women to a sample of non-pregnant women. It is
interesting to note the higher incidence of fever ob-
served in non-pregnant female HCWs, which mayadverse event following trivalent influenza vaccination – FASTMum,
Table 2 Medical attendance of adverse events following influenza immunisation among pregnant and non-pregnant
women – FASTMum, Western Australia, Australia, 19 March-15 May 2014
Pregnant (n = 947) Non-pregnant (n = 275) Fisher’s exact
test p-value
AOR
p-valuen Percent (95% CI) n Percent (95% CI)
Reaction requiring any treatment** 52 5.5 (4.0-6.9) 26 9.5 (6.0-12.9) .02 .06
Reaction requiring telephone advice 11 1.2 (0.5-1.8) 2 0.8 (0.0-2.0) .74 .95
Telephoned a doctor 7 0.7 (0.2-1.3) 0 0.0 (0.0-0.1) .36 .95
Telephoned other 4 0.4 (0.0-0.8) 2 0.8 (0.0-2.0) .62 .78
Reaction requiring medical attention 12 1.3 (0.5-2.0) 1 0.4 (0.0-1.2) .32 .18
Visited a doctor 8 0.8 (0.3-1.4) 1 0.4 (0.0-1.2) .69 .45
Visited a hospital emergency department 4 0.4 (0.0-0.8) 0 (0.0-0.1) .58 .96
**A reaction requiring treatment was defined as any reaction where the woman reported self-treating with an antipyretic or pain reliever or visiting a doctor,
medical centre or hospital emergency department to seek treatment.
AOR, adjusted odds ratio – adjusted for age and residence (metropolitan/non-metropolitan).
CI, confidence interval.
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events. Such an occurrence is not implausible consider-
ing previous research has shown pregnancy can have a
protective effect against medical conditions, such as
breast cancer [19,20] and rheumatoid arthritis, due to
hormonal and immunological changes induced by preg-
nancy [21]. Alternatively, it is possible these differences
were observed due to reporting differences in the groups
of women. Non-pregnant female HCWs are likely not a
perfect comparison group. Because of their profession
and potential knowledge of simple remedies, HCWs are
a unique subset of vaccinees with distinctive health-
seeking behaviours and perceptions of health. As a re-
sult, it is possible that the incidence of reported fever is
more a reflection on the perception of fever, and the
threshold for subjective fever may differ between
HCWs and other cohorts. Another possible explan-
ation for the observation that more HCWs reported
fever is that pregnant women may expect or be accus-
tomed to fluctuations in symptomatology related to
their pregnancy and therefore do not attribute such
symptoms to vaccination. However, these explanations
are speculative, and additional studies would be re-
quired to explore further. In any event, our study
found nothing to suggest pregnant women are more
likely to report experiencing a reaction to inactivated
influenza vaccine, compared to non-pregnant women
of similar age.
There are several other limitations which should be
considered when evaluating these results. First, the reac-
tions were self-reported and generally not medically
attended, thus they are subject to reporting biases. Sec-
ondly, we also identified demographic differences be-
tween these groups of women, most likely due to the
younger age distribution of pregnant women compared
to non-pregnant women and the preferential distribution
of intradermal TIV in metropolitan HCW vaccination
programs. However, we addressed these differences bycontrolling for differences in age and residence in the
analysis.Conclusions
Our results indicate that pregnant women experience
similar rates of vaccine-associated side effects as non-
pregnant women, and these findings can be used to
reassure pregnant women who are wary of influenza vac-
cination due to concerns about side effects. Continued
monitoring of vaccine safety and reactogenicity is an in-
tegral component of vaccination campaigns [22]. Rapid,
timely and relevant vaccine safety information can be
collected using systems such as FASTMum. Integration
of such data collection into vaccination programs would
facilitate communication of vaccine safety information
in a timely manner to pregnant women and antenatal
care providers, promoting better informed decision-
making regarding antenatal vaccination.Competing interests
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